A Phase 2 Randomized, Multicenter, Doubleblind, Vehicle Controlled, 12 Week, Safety, Efficacy & Systemic Exposure Study Followed by a 12 Week Open-label Extension of CD5789 in Adults and Adolescents With Autosomal Recessive Ichthyosis With Lamellar Scale
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2019
Price : $35 *
At a glance
- Drugs Trifarotene (Primary)
- Indications Ichthyosis
- Focus Therapeutic Use
- Sponsors Mayne Pharma
- 05 Sep 2019 Status changed from not yet recruiting to recruiting.
- 14 Feb 2019 Planned initiation date changed from 21 Jan 2019 to 21 Feb 2019.
- 19 Nov 2018 New trial record